St. Jude Begins Renal Denervation Study

Medical device maker St. Jude Medical (NYSE: STJ  ) announced in a press statement Wednesday that it has enrolled the first patient in a clinical trial of its EnligHTN renal denervation device. The study, dubbed the EnligHTN II trial, will judge the safety and efficacy of St. Jude's product in patients with uncontrolled hypertension.

The EnligHTN is currently cleared by regulators overseas in treating drug-resistant hypertension, but this latest trial will build on that by enrolling up to 500 patients at 40 sites across Europe and Australia. The EnligHTN II trial also hopes to back the blood pressure-lowering results of the EnligHTN I trial, an earlier hypertension study from St. Jude.

Dr. Johannes Brachmann expanded upon renal denervation in the company press release, saying, "There is convincing evidence from studies like the EnligHTN I trial linking renal denervation to improved blood pressure in patients who have drug-resistant hypertension...Expanding this research to patients with less severe forms of hypertension is important as this minimally invasive approach allows for a shorter procedure time and a potentially faster recovery time, which may benefit more patients with uncontrolled hypertension."

According to the release, data from the World Health Organization shows that one in three adults around the globe have higher-than-normal blood pressure.

link


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2227437, ~/Articles/ArticleHandler.aspx, 9/20/2014 4:04:28 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement